UY25946A1 - Un método para probar la pureza o estabilidad a la degradación de una muestra de lamotrigina o una formulación farmacéutica en dosis que incluya lamotrigina - Google Patents

Un método para probar la pureza o estabilidad a la degradación de una muestra de lamotrigina o una formulación farmacéutica en dosis que incluya lamotrigina

Info

Publication number
UY25946A1
UY25946A1 UY25946A UY25946A UY25946A1 UY 25946 A1 UY25946 A1 UY 25946A1 UY 25946 A UY25946 A UY 25946A UY 25946 A UY25946 A UY 25946A UY 25946 A1 UY25946 A1 UY 25946A1
Authority
UY
Uruguay
Prior art keywords
sample
lamotrigine
compound
triazine
amino
Prior art date
Application number
UY25946A
Other languages
English (en)
Inventor
Niger Arthur Griffith Skinner
Graham Thronton Hill
Derek Anthony Hill
Lorraine Mary Edmeades
Terence William Packham
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25946(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of UY25946A1 publication Critical patent/UY25946A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Abstract

Un método para probar la pureza o estabilidad a la degradación de una muestra de lamotrigina o una formulación farmacéutica en dosis que incluya lamotrigina, comprende la realización de ensayos con dicha muestra para detectar la presencia de un compuesto seleccionado de 3-amino-6-(2,3-diclorofenil)-1,2,4-triazina-5-(4h)-ona y N-[5-amino-6-(2,3-diclorofeni)-1,2.4-triazina-3-il]-2.3-diclorobenzamida (fórmula l) asimismo, también se revela un proceso, para la producción del compuesto de fórmula l. Un método para probar la pureza de una muestra de lamotrigina, que incluye estos pasos: 1- disolver una muestra de lamotrigina en un solvente para producir una solución de muestra; 2- disolver una muestra de uno-3-amino-6-(2,3-diclorofenil)-1,2,4-triazina-5-(4H) o N-[5-amino-6-(2,3-diclorofeni)-1,2.4-triazina-3-il]-2.3-diclorobenzamida en un solvente para producir una solución estandar como marcador de referencia; 3- someter la solución de muestra y la solución estandar a cromatografía en capa fina para obtener un cromatograma TLC para cada una; y 4- estimar la intensidad de cualquier mancha secundaria obtenida en el cromatograma de la solución de muestra, que corresponde en valor de respuesta, al marcador de referencia, en contraposición a la mancha debida al marcador de referencia en el cromatograma de la solución estandar. Un proceso para producir el compuesto b, cuyo proceso comprende: 1- la reacción de dos equivalentes de cloruro de 2,3-diclorobenzoilo con 1 equivalente de lamotrigina disuelta en piridina a una temp. de menos de 35sC; o 2- ciclizar un compuesto de fórmula l en propan 1-ol bajo reflujo. Un proceso en donde en el paso 2 el compuesto de fórmula l se produce haciendo juntos a los compuestos de la formulas ll y lll en presencia de ácido mineral.
UY25946A 1998-06-10 2000-01-17 Un método para probar la pureza o estabilidad a la degradación de una muestra de lamotrigina o una formulación farmacéutica en dosis que incluya lamotrigina UY25946A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (1)

Publication Number Publication Date
UY25946A1 true UY25946A1 (es) 2000-12-29

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25946A UY25946A1 (es) 1998-06-10 2000-01-17 Un método para probar la pureza o estabilidad a la degradación de una muestra de lamotrigina o una formulación farmacéutica en dosis que incluya lamotrigina

Country Status (31)

Country Link
US (1) US6333198B1 (es)
EP (2) EP0963980B1 (es)
JP (1) JP2989189B1 (es)
KR (1) KR100322354B1 (es)
CN (2) CN1238454A (es)
AP (3) AP9901481A0 (es)
AR (1) AR014074A1 (es)
AT (1) ATE218552T1 (es)
AU (1) AU2031999A (es)
BR (1) BR9900984A (es)
CA (1) CA2265194C (es)
DE (1) DE69901656T2 (es)
DK (1) DK0963980T3 (es)
EA (1) EA000666B1 (es)
ES (1) ES2178342T3 (es)
GB (1) GB9812413D0 (es)
HR (1) HRP990074A2 (es)
HU (1) HUP9900592A3 (es)
ID (1) ID22957A (es)
MA (1) MA24777A1 (es)
NO (2) NO991151L (es)
NZ (1) NZ334590A (es)
PE (1) PE20000332A1 (es)
PL (1) PL331870A1 (es)
PT (1) PT963980E (es)
SG (1) SG85628A1 (es)
SI (1) SI0963980T1 (es)
TR (1) TR199900520A2 (es)
UY (1) UY25946A1 (es)
YU (1) YU12399A (es)
ZA (1) ZA991951B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
AU763244B2 (en) * 2000-01-03 2003-07-17 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
MXPA03005884A (es) 2000-12-29 2005-04-08 Pfizer Ltd Hemimaleato de amlodipina.
SI1309555T1 (sl) 2000-12-29 2005-12-31 Pfizer Ltd Postopek izdelave amlodipin-maleata
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
MXPA03005886A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado de aspartato de amlodipina como antagonista del canal de calcio.
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
WO2002054062A2 (en) * 2000-12-29 2002-07-11 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
BR0116554A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
DE10134980C2 (de) 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
US20030216376A1 (en) * 2002-03-20 2003-11-20 Revital Lifshitz-Liron Crystalline forms of quetiapine hemifumarate
HU225667B1 (en) * 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
EP1562912A2 (en) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
KR100887264B1 (ko) 2003-12-02 2009-03-06 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 특성화를 위한 기준 표준물
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
EP1708708A1 (en) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
CA2554789A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries, Ltd. Montelukast sodium polymorphs
MD2823G2 (ro) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
JP2007532686A (ja) * 2004-04-21 2007-11-15 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムを調製する方法
JP2007532585A (ja) 2004-04-26 2007-11-15 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸及びそのエステル誘導体の調製方法
EP1740563A2 (en) * 2004-04-27 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Mycophenolate mofetil impurity
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
ATE407111T1 (de) * 2004-06-28 2008-09-15 Teva Pharm Fine Chemicals Srl Isolierte atomoxetinverunreinigung, verfahren zur herstellung von atomoxetinverunreinigungen und deren verwendung als referenzstandards
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
WO2006012379A2 (en) * 2004-07-20 2006-02-02 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Processes for preparation of crystalline mycophenolate sodium
WO2006020348A2 (en) * 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
CA2578750A1 (en) * 2004-09-04 2006-03-16 Teva Pharmaceutical Industries, Ltd. A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
ES2263407T1 (es) * 2004-09-28 2006-12-16 Teva Pharmaceutical Industries Ltd Procedimiento para la preparacion de formas de atorvastatina calcica sustancialmente libres de impurezas.
CA2582090A1 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
WO2006071868A2 (en) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
PT1836157E (pt) * 2005-01-11 2009-11-24 Teva Pharm Fine Chemicals Srl Polimorfos de cloridrato de memantina
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
ES2389565T3 (es) 2005-02-22 2012-10-29 Teva Pharmaceutical Industries Ltd. Rosuvastatina y sales de la misma carentes de alquiléter de rosuvatatina y un procedimiento para la preparación de las mismas
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
CA2602073A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
US7534900B2 (en) * 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
US7569729B2 (en) * 2005-04-05 2009-08-04 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
CN101160281A (zh) * 2005-04-06 2008-04-09 特瓦制药工业有限公司 结晶形态的普瑞巴林
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
US20070066846A1 (en) * 2005-04-11 2007-03-22 Asher Maymon Process for making (S)-Pregabalin
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CA2604600A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabalin free of isobutylglutaric acid and a process for preparation thereof
KR100893312B1 (ko) * 2005-05-10 2009-04-15 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린 및 이의 염의 제조 방법
CA2604624A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
WO2006121557A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
EP1975150A1 (en) 2005-05-23 2008-10-01 Teva Pharmaceutical Industries Ltd. Cinacalcet salts
WO2007002720A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. An impurity of anastrozole intermediate, and uses thereof
KR20080015438A (ko) * 2005-06-27 2008-02-19 시코르, 인크. 아나스트로졸 중간체의 불순물, 및 이의 용도
JP2008510840A (ja) * 2005-07-05 2008-04-10 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストの精製
WO2007022488A2 (en) * 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
KR20070087596A (ko) * 2005-09-19 2007-08-28 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ)-(+)-3-(아미노메틸)-5-메틸헥산산의 비대칭 합성
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
US20070203221A1 (en) * 2005-12-27 2007-08-30 Valeriano Merli Processes for preparing darifenacin hydrobromide
CA2644819A1 (en) * 2006-03-27 2007-11-08 Teva Pharmaceutical Fine Chemicals S.R.L. Process for preparing memantine hydrochloride substantially free of impurities
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
KR20080027880A (ko) * 2006-05-24 2008-03-28 테바 파마슈티컬 인더스트리즈 리미티드 Ｒ-(+)-3-(카바모일메틸)-5-메틸헥산산 및 이의 염의 제조방법
EP1912931A2 (en) * 2006-05-31 2008-04-23 Teva Pharmaceutical Industries Ltd. Preparation of (s)-pregabalin-nitrile
KR20080036060A (ko) * 2006-05-31 2008-04-24 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린의 중간체의 제조에 효소 분할을 이용하는 방법
ES2339297T3 (es) * 2006-06-29 2010-05-18 Ivax Pharmaceuticals S.R.O. Regulacion de la produccion de metabolitos acidos.
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CN101506178A (zh) * 2006-08-14 2009-08-12 隆沙有限公司 制备拉莫三嗪的方法
EP2139845A1 (en) * 2007-02-26 2010-01-06 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
BRPI0803092A2 (pt) * 2007-03-22 2011-08-30 Teva Pharma sìntese de (s)-(+)-3-(aminometil)-5-metil ácido hexanóico, (s)-pregabalina
BRPI0803097A2 (pt) * 2007-04-11 2011-11-08 Teva Gyogyszergyar ... método para redução do nìvel de impurezas na fermentação do ácido micofenólico
WO2008151170A2 (en) * 2007-05-31 2008-12-11 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
US20090137842A1 (en) * 2007-10-03 2009-05-28 Vollerner Yuri Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
JP2010539156A (ja) * 2007-10-23 2010-12-16 テバ ファーマシューティカル インダストリーズ リミティド ダサチニブ多形体およびその調製プロセス
US20090281176A1 (en) * 2007-11-01 2009-11-12 Vinod Kumar Kansal Process for the synthesis of ramelteon and its intermediates
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine
CA2717580A1 (en) * 2008-03-06 2009-12-17 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010045565A1 (en) * 2008-10-16 2010-04-22 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
CA2795023A1 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
WO2015092819A2 (en) * 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
CN110467560A (zh) 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK153787C (da) 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
EP0021120B1 (en) 1979-06-01 1983-04-06 The Wellcome Foundation Limited 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
WO1996020934A1 (en) * 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Also Published As

Publication number Publication date
AP9901481A0 (en) 1999-03-31
CN1238454A (zh) 1999-12-15
PE20000332A1 (es) 2000-04-10
HRP990074A2 (en) 2000-10-31
CA2265194C (en) 2000-10-10
AU2031999A (en) 2000-01-06
EP0963980B1 (en) 2002-06-05
NO991151D0 (no) 1999-03-10
HU9900592D0 (en) 1999-04-28
PL331870A1 (en) 1999-12-20
AP0102286A0 (en) 2000-09-10
ATE218552T1 (de) 2002-06-15
NO991151L (no) 1999-12-13
EP1170588A1 (en) 2002-01-09
AP2001002286A0 (en) 2001-12-31
NO20032753L (no) 1999-12-13
EA199900159A1 (ru) 1999-12-29
BR9900984A (pt) 2000-05-02
KR100322354B1 (ko) 2002-02-07
TR199900520A3 (tr) 2000-01-21
ZA991951B (en) 1999-08-16
MA24777A1 (fr) 1999-10-01
EP0963980A3 (en) 2000-05-31
EP0963980A2 (en) 1999-12-15
NZ334590A (en) 2000-07-28
YU12399A (sh) 2002-08-12
DE69901656D1 (de) 2002-07-11
ID22957A (id) 1999-12-23
NO20032753D0 (no) 2003-06-17
ES2178342T3 (es) 2002-12-16
JP2989189B1 (ja) 1999-12-13
AR014074A1 (es) 2001-01-31
EA000666B1 (ru) 2000-02-28
HUP9900592A2 (hu) 2000-04-28
DE69901656T2 (de) 2003-01-30
DK0963980T3 (da) 2002-09-16
CN1306210A (zh) 2001-08-01
TR199900520A2 (en) 2000-01-21
SG85628A1 (en) 2002-01-15
PT963980E (pt) 2002-10-31
JP2000009714A (ja) 2000-01-14
US6333198B1 (en) 2001-12-25
GB9812413D0 (en) 1998-08-05
SI0963980T1 (en) 2002-12-31
KR20000005611A (ko) 2000-01-25
HUP9900592A3 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
UY25946A1 (es) Un método para probar la pureza o estabilidad a la degradación de una muestra de lamotrigina o una formulación farmacéutica en dosis que incluya lamotrigina
Grob et al. The Derivation of Inductive Substituent Constants from pKa Values of 4‐Substituted Quinuclidines. Polar effects. Part I
FI852902L (fi) Ny mellanprodukt och metod foer framstaellning daerav.
EA200200770A1 (ru) Производные пурина
EA200101107A1 (ru) Пуриновые производные
ES2061580T3 (es) Compuestos de 3,7-diazabiciclo(3,3,1)nonano, asi como procedimiento para su preparacion y medicamentos que contienen estos compuestos.
KIKUGAWA et al. Studies on peroxidized lipids. I. Interaction of malondialdehyde with secondary amines and its relevance to nitrosamine formation
ES2142763B1 (es) Derivados de 5'-desoxicitidina.
Andrisano et al. Photodegradation studies on atenolol by liquid chromatography
IT1139974B (it) Derivati della s-adenosilmetionina,processo per la preparazione e composizioni terapeutiche che li contengono come principio attivo
Zhao et al. Quantification of imatinib and related compounds using capillary electrophoresis‐tandem mass spectrometry with field‐amplified sample stacking
DK493485D0 (da) Piperazinylindanderivater, syreadditionssalte deraf og farmaceutiskekompositioner
Kapetanovic et al. Analysis of the antimalarial, mefloquine, in blood and plasma using high-performance liquid chromatography
EA200400848A1 (ru) Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов
Jacob et al. Determination of nicotine N-oxide by gas chromatography following thermal conversion to 2-methyl-6-(3-pyridyl) tetrahydro-1, 2-oxazine
Aaron et al. Fluorimetric and phosphorimetric characteristics of several vitamins
ES543368A0 (es) Procedimiento para la obtencion de derivados de 1-fluoro-1- -azolil-2,2-diaril-etano
Momerency et al. Determination of iphosphamide and seven metabolites in blood plasma, as stable trifluoroacetyl derivatives, by electron capture chemical ionization GC‐MS
Danhof et al. 3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine
ES2037770T3 (es) Procedimiento para la preparacion de intermediarios para la sintesis de fosfomicina.
Wallén et al. High-performance liquid chromatographic method for the enantioselective analysis of mefloquine in plasma and urine
Pillai et al. Analysis of barbiturates by gas chromatography
Shetty et al. Piperazine ring cleavage in the electron impact induced fragmentation of piperazine type phenothiazine antipsychotic agents
Labbe-Bois et al. Quantitative structure-activity relations for dicoumarol antivitamins K in the uncoupling of mitochondrial oxidative phosphorylation
ES8900107A1 (es) Un procedimiento para preparar derivados de alcanoles heteropoliciclicos